Combination of SFRP2 and PD-1 immunotherapy halts aggressive metastatic cancer in pre
In a cancer that has not seen new targeted therapies for over 20 years, MUSC Hollings Cancer Center researcher and oncologist Nancy Klauber-DeMore, M.D., is pioneering new discoveries.